Anti-angiogenic effects caused by the decreased the number and the functional change of endothelial cells by the mIFN-β treatment may be involved in the enlargement of necrotic areas induced in vivo, although we were unable to completely clarify the detailed antitumor mechanisms regarding combination therapy with sorafenib and type-І IFNs for HCC. Here, SGCG is linked to hepatocellular carcinoma.